Boston Scientific (BSX): Impax Asset Management Group plc reduced its stake -15K shares
Impax Asset Management Group plc reduced its stake in Boston Scientific, per its Q2 2025 13F.
- 1.45M
- Shares reported · -15K vs prior quarter
- 0.89%
- Disclosed portfolio weight
- $154M
- Reported value
- Holdings as of
- Jun 30, 2025
- Filed
- Aug 8, 2025
What stands out in this filing
- 1,464,770 shares in Q1 2025, 1,449,736 now (−1.0% in share count).
- Reported at $154M, 0.89% of the portfolio value in this 13F filing.
- 74 other tracked managers reported the same kind of change for Q2 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 29, 2024CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Dec 11, 2024CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- May 12, 2025CongressDisclosed sale of BSX — reported range $15,001 - $50,000
- Jun 11, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Jun 26, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Jul 1, 2025InsiderOfficer sold ~$5.35M of BSX shares in the open market
- Jul 25, 2025InsiderDirector sold ~$424K of BSX shares in the open market
- Jul 29, 2025InsiderDirector sold ~$310K of BSX shares in the open market
- Jul 31, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Aug 1, 2025Insider · 2 peopleInsiders: 2 sales (~$7.0M)
- Aug 4, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
What came next
- Sep 2, 2025Insider · 1 personInsiders: 2 sales (~$5.3M)
- Sep 11, 2025FDARecall: TENACIO Pump without InhibiZone; UPN: 72404420;
- Sep 11, 2025FDARecall: TENACIO Pump with InhibiZone; UPN: 72404429;
- Sep 11, 2025FDARecall: LGX Preconnect with TENACIO Pump without InhibiZone; UPNs: (1) 72404405 (12CM IP), (2) 72404407 (18CM IP);
- Sep 11, 2025FDARecall: CXR Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404461 (12CM PS IZ), (2) 72404462 (14CM PS IZ), (3) 72404463 (16CM PS IZ), (4) 72404464 (18C…
- Sep 11, 2025FDARecall: CX Preconnect with TENACIO Pump without InhibiZone; UPNs: (1) 72404486 (15CM IP), (2) 72404488 (21CM IP);
- Sep 11, 2025FDARecall: LGX Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404450 (12CM PS IZ), (2) 72404451 (15CM PS IZ), (3) 72404452 (18CM PS IZ), (4) 72404453 (21C…
- Sep 11, 2025FDARecall: CX Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404430 (12CM PS IZ), (2) 72404431 (15CM PS IZ), (3) 72404432 (18CM PS IZ), (4) 72404433 (21CM…
- Sep 12, 2025FDAFDA device clearance: LUX-Dx II Insertable Cardiac Monitor (M302); LUX-Dx II+ Insertable Cardiac Monitor (M312)
- Sep 23, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
- Sep 24, 2025FDAFDA device clearance: LithoVue Elite Single-Use Digital Flexible Ureteroscope - Standard with pressure monitoring (M0067940000); LithoVue Elite Single-Use Digital Flexible Ureterosc…
- Sep 26, 2025FDAFDA device clearance: Radial Jaw 4 Pulmonary Biopsy Forceps
- Oct 9, 2025FDAFDA device clearance: Orca Air/Water and Suction Valves
- Oct 17, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Oct 22, 2025Company filing · Form 8-K · ResultsReported its results
- Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, John E. Sununu informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
- Oct 27, 2025InsiderDirector sold ~$1.01M of BSX shares in the open market
- Oct 28, 2025FDAFDA device clearance: TheraSphere 360 Y-90 Management Platform
- Oct 28, 2025InsiderDirector sold ~$297K of BSX shares in the open market
- Oct 28, 2025CongressDisclosed partial sale of BSX — reported range $15,001 - $50,000
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Boston Scientific
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.
How this filing works
Explore the data
Common questions
What does this filing report about Boston Scientific (BSX) stock?
Impax Asset Management Group plc reduced its stake in Boston Scientific, per its Q2 2025 13F. Now 1.45M shares, $154M reported value, 0.89% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Jun 30, 2025. Filed: Aug 8, 2025.
What stands out in this filing?
1,464,770 shares in Q1 2025, 1,449,736 now (−1.0% in share count). Reported at $154M, 0.89% of the portfolio value in this 13F filing. 74 other tracked managers reported the same kind of change for Q2 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Boston Scientific recently?
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.
Does this mean BSX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Boston Scientific
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
Everything OQRO holds on this company is on its BSX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
